🟢 Ultragenyx is trading 4.6% up today after record Q2 revenue beat

Ultragenyx is trading 4.6% up now at $26.07 after investors continued reacting to its August 4 earnings release and record second-quarter revenue.

• Second-quarter revenue reached a record $214 million, topping roughly $182 million consensus; 2026 revenue guidance was reaffirmed at $730 million-$760 million.
• Upcoming gene-therapy regulatory decisions include DTX401’s August 23 PDUFA date.
• XBI is up 2.09%, supporting the biotech rally, while major U.S. indexes are mixed; the company-specific earnings catalyst appears primary.